Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
Abstract Background Recently, therapeutic antibodies against programmed cell death 1 (PD-1) and its ligand (PD-L1) have exerted potent anticancer effect in a variety of tumors. However, blocking the PD-1/PD-L1 axis alone is not sufficient to restore normal immune response. Other negative regulators...
Main Authors: | Mengke Niu, Ming Yi, Yuze Wu, Lijuan Lyu, Qing He, Rui Yang, Liang Zeng, Jian Shi, Jing Zhang, Pengfei Zhou, Tingting Zhang, Qi Mei, Qian Chu, Kongming Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-08-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13045-023-01487-5 |
Similar Items
-
Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
by: Tianye Li, et al.
Published: (2023-07-01) -
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
by: Ming Yi, et al.
Published: (2022-10-01) -
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
by: Tianye Li, et al.
Published: (2024-03-01) -
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
by: Ming Yi, et al.
Published: (2021-02-01) -
Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers
by: Ming Yi, et al.
Published: (2021-09-01)